Sophiris Bio Inc fka SPHS

[cwarner]

The difference is that the 12 week interim efficacy standard is different than the 52 week primary endpoint. The 12 week interim analysis threshold was a difference of 2.0 IPSS points above the placebo. According to PRs, the primary endpoint is just achieving a statistical difference over the baseline. Look at the phase 2 trial data to see how far it was above baseline then.